Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
15 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY TYPE
15.1 OVERVIEW
15.2 MARKETED DRUGS
15.2.1 MEK INHIBITORS
15.2.1.1. TRAMETINIB
15.2.1.1.1. MARKET VALUE (USD MILLION)
15.2.1.1.2. MARKET VOLUME (UNITS)
15.2.1.1.3. AVERAGE SELLING PRICE (ASP)
15.2.1.2. COBIMETINIB
15.2.1.2.1. MARKET VALUE (USD MILLION)
15.2.1.2.2. MARKET VOLUME (UNITS)
15.2.1.2.3. AVERAGE SELLING PRICE (ASP)
15.2.1.3. SELUMETINIB
15.2.1.3.1. MARKET VALUE (USD MILLION)
15.2.1.3.2. MARKET VOLUME (UNITS)
15.2.1.3.3. AVERAGE SELLING PRICE (ASP)
15.2.1.4. OTHERS
15.2.2 BRAF INHIBITORS
15.2.2.1. VEMURAFENIB
15.2.2.1.1. MARKET VALUE (USD MILLION)
15.2.2.1.2. MARKET VOLUME (UNITS)
15.2.2.1.3. AVERAGE SELLING PRICE (ASP)
15.2.2.2. DEBRAFENIB
15.2.2.2.1. MARKET VALUE (USD MILLION)
15.2.2.2.2. MARKET VOLUME (UNITS)
15.2.2.2.3. AVERAGE SELLING PRICE (ASP)
15.2.2.3. ENCORAFENIB
15.2.2.3.1. MARKET VALUE (USD MILLION)
15.2.2.3.2. MARKET VOLUME (UNITS)
15.2.2.3.3. AVERAGE SELLING PRICE (ASP)
15.2.2.4. OTHERS
15.3 EMERGING DRUGS
15.3.1 SB681323
15.3.1.1. MARKET VALUE (USD MILLION)
15.3.1.2. MARKET VOLUME (UNITS)
15.3.1.3. AVERAGE SELLING PRICE (ASP)
15.3.2 PD184352
15.3.2.1. MARKET VALUE (USD MILLION)
15.3.2.2. MARKET VOLUME (UNITS)
15.3.2.3. AVERAGE SELLING PRICE (ASP)
15.3.3 PD0325901
15.3.3.1. MARKET VALUE (USD MILLION)
15.3.3.2. MARKET VOLUME (UNITS)
15.3.3.3. AVERAGE SELLING PRICE (ASP)
15.3.4 ARRY-371797
15.3.4.1. MARKET VALUE (USD MILLION)
15.3.4.2. MARKET VOLUME (UNITS)
15.3.4.3. AVERAGE SELLING PRICE (ASP)
15.3.5 AZD6244
15.3.5.1. MARKET VALUE (USD MILLION)
15.3.5.2. MARKET VOLUME (UNITS)
15.3.5.3. AVERAGE SELLING PRICE (ASP)
15.3.6 MEK162
15.3.6.1. MARKET VALUE (USD MILLION)
15.3.6.2. MARKET VOLUME (UNITS)
15.3.6.3. AVERAGE SELLING PRICE (ASP)
15.3.7 GILTERITINIB
15.3.7.1. MARKET VALUE (USD MILLION)
15.3.7.2. MARKET VOLUME (UNITS)
15.3.7.3. AVERAGE SELLING PRICE (ASP)
15.3.8 ERAS-601
15.3.8.1. MARKET VALUE (USD MILLION)
15.3.8.2. MARKET VOLUME (UNITS)
15.3.8.3. AVERAGE SELLING PRICE (ASP)
15.3.9 OTHERS
16 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY INDICATION
16.1 OVERVIEW
16.2 ONCOLOGY
16.2.1 BY TYPE
16.2.1.1. MARKETED DRUGS
16.2.1.2. EMERGING DRUGS
16.2.2 BY CANCER TYPE
16.2.2.1. BREAST CANCER
16.2.2.2. LUNG CANCER
16.2.2.3. COLORECTAL CANCER
16.2.2.4. PANCREATIC CANCER
16.2.2.5. MELANOMA
16.2.2.6. SOLID TUMORS
16.2.2.7. OTHERS
16.3 HEPATOLOGY
16.3.1 MARKETED DRUGS
16.3.2 EMERGING DRUGS
16.4 RESPIRATORY DISORDERS
16.4.1 MARKETED DRUGS
16.4.2 EMERGING DRUGS
16.5 OTHERS
17 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
17.1 OVERVIEW
17.2 PARENTERAL
17.3 ORAL
17.4 OTHERS
18 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY DOSAGE FORM
18.1 OVERVIEW
18.2 ORAL
18.2.1 CAPSULES
18.2.2 TABLETS
18.2.3 OTHERS
18.3 INTRAVENOUS
18.4 SUBCUTANOUS
18.5 OTHERS
19 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY AGE GROUP
19.1 OVERVIEW
19.2 ADULT
19.3 GERIARTIC
19.4 PEDIATRIC
20 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.3 SPECIALTY CLINICS
20.4 HOME CARE
20.5 ONCOLOGY CENTERS
20.6 ACADEMIC & RESEARCH INSTITUTES
20.7 OTHERS
21 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.3.1 HOSPITAL PHARMACIES
21.3.2 ONLINE PHARMACIES
21.3.3 OTHERS
21.4 OTHERS
22 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, BY REGION
Global MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS Market, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 U.K.
23.2.3 ITALY
23.2.4 FRANCE
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 SWITZERLAND
23.2.8 TURKEY
23.2.9 BELGIUM
23.2.10 NETHERLANDS
23.2.11 DENMARK
23.2.12 SWEDEN
23.2.13 POLAND
23.2.14 NORWAY
23.2.15 FINLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 SINGAPORE
23.3.6 THAILAND
23.3.7 INDONESIA
23.3.8 MALAYSIA
23.3.9 PHILIPPINES
23.3.10 AUSTRALIA
23.3.11 NEW ZEALAND
23.3.12 VIETNAM
23.3.13 TAIWAN
23.3.14 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 EGYPT
23.5.3 BAHRAIN
23.5.4 UNITED ARAB EMIRATES
23.5.5 KUWAIT
23.5.6 OMAN
23.5.7 QATAR
23.5.8 SAUDI ARABIA
23.5.9 REST OF MEA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS THERAPEUTICS MARKET, COMPANY PROFILE
24.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 ASTRAZENECA
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 PFIZER INC.
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 NOVARTIS PHARMACEUTICALS CORPORATION.
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 F. HOFFMANN-LA ROCHE LTD
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 BAYER AG
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 ERASCA, INC.
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 JAZZ PHARMACEUTICALS PLC
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 BIOMED VALLEY DISCOVERIES, INC.
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 POOLBEG PHARMA
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 IMMUNEERING CORPORATION
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 SPRINGWORKS THERAPEUTICS, INC.
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 FOCHON PHARMACEUTICALS LTD.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 HUTCHMED
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 KINARUS AG
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 CHUGAI PHARMACEUTICAL CO., LTD.
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 BRIDGEBIO INC.
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 BEIGENE, INC.
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 SEAGEN INC.
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
24.21 APOLLOMICS, INC.
24.21.1 COMPANY OVERVIEW
24.21.2 REVENUE ANALYSIS
24.21.3 GEOGRAPHIC PRESENCE
24.21.4 PRODUCT PORTFOLIO
24.21.5 RECENT DEVELOPMENTS
24.22 KURA ONCOLOGY, INC.
24.22.1 COMPANY OVERVIEW
24.22.2 REVENUE ANALYSIS
24.22.3 GEOGRAPHIC PRESENCE
24.22.4 PRODUCT PORTFOLIO
24.22.5 RECENT DEVELOPMENTS
24.23 HANMI PHARM.CO.,LTD.
24.23.1 COMPANY OVERVIEW
24.23.2 REVENUE ANALYSIS
24.23.3 GEOGRAPHIC PRESENCE
24.23.4 PRODUCT PORTFOLIO
24.23.5 RECENT DEVELOPMENTS
24.24 RECURSION PHARMACEUTICALS, INC.
24.24.1 COMPANY OVERVIEW
24.24.2 REVENUE ANALYSIS
24.24.3 GEOGRAPHIC PRESENCE
24.24.4 PRODUCT PORTFOLIO
24.24.5 RECENT DEVELOPMENTS
24.25 ABM
24.25.1 COMPANY OVERVIEW
24.25.2 REVENUE ANALYSIS
24.25.3 GEOGRAPHIC PRESENCE
24.25.4 PRODUCT PORTFOLIO
24.25.5 RECENT DEVELOPMENTS
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
